Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Evaluation of marketed soft contact [CONTACT_722692]-6483
Version: 3.0Date: 09 February 2022
Investigational Products:  None
Keywords:  Sphere platform, Study lens: delefilcon A (Dailies Total 1), daily wear, daily 
disposable, dispensing, Revitale ns, subjective performance. 
Statement of Compliance to protocol, GCP and applicable reg ulatory guidelines: 
This trial will be conducted in compliance with the protocol, ISO [ZIP_CODE]:2020,
0the 
International Council for Harmonization G ood Clinical Practice E6(R2) (ICH GCP),0 the 
Declaration of Helsinki,0 and all applicable re gulatory requirements. 
Confidentiality Statement:
This document contains confidential information, which shoul d not be copi[INVESTIGATOR_530], referred to, 
released or published without  written approval from [COMPANY_012] Vision Care, Inc. The 
information may not be disclosed to others except to the extent necessary to obtain Institutional Review Board/Independent Ethics Committee approval and informed consent, or as required by [CONTACT_19543], Federal and State Laws, as app licable. Persons to whom this information is 
disclosed must be informed that this information is privileged and confidential and that it should not be further disclosed without the written permission of [COMPANY_012] Vision 
Care, Inc. Any supplemental information that  may be added to this document is also 
confidential and proprie tary to [COMPANY_012] Vision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this document. 
CR-6483, v 3.0  
Page 1 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
TABLE OF CONTENTS
PROTOCOL TITLE, NUMBER, VERSION AND DATE...................................................... [ADDRESS_986977] Article Allocation ............................................................................................. 20  
5.2. Masking .................................................................................................................... 20  
5.3. Procedures for Maintaining and Breaking the Masking........................................... 20  
6. STUDY INTERVENTION ............................................................................................. 21  
CR-6483, v 3.0  
Page 2 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
6.1. Identity of Test Articles............................................................................................ 21  
6.2. Ancillary Supplies/Products ..................................................................................... [ADDRESS_986978] Articles ................................................................................ 22  
7. STUDY EVALUATIONS .............................................................................................. 23  
7.1. Time and Event Schedule ......................................................................................... 23  
7.2. Detailed Study Procedures ....................................................................................... 24  
VISIT 1 ........................................................................................................................... 24  
VISIT 2 ........................................................................................................................... 30  
FINAL EVALUATION .................................................................................................. 32  
7.3. Unscheduled Visits ................................................................................................... 32  
7.4. Laboratory Procedures ............................................................................................. 34  
8. SUBJECTS COMPLETION/WITHDRAWAL.............................................................. 34  
8.1. Completion Criteria .................................................................................................. 34  
8.2. Withdrawal/Discontinua tion from the Study ........................................................... 34  
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. [ADDRESS_986979] QUALITY COMPLAINTS .............. 39  
13. ADVERSE EVENTS ................................................................................................... 40  
13.1.  Definitions and Classifications ............................................................................. 40  
13.2.  Assessing Adverse Events .................................................................................... 42  
13.2.1.  Causality Assessment .................................................................................... 43  
13.2.2.  Severity Assessment ...................................................................................... 43  
13.3.  Documentation and Follow-Up of Adverse Events .............................................. 44  
13.4.  Reporting Adverse Events .................................................................................... 45  
13.4.1.  Reporting Adverse Events to Sponsor .......................................................... 45  
13.4.2.  Reporting Adverse Events to the Respons ible IEC/IRB and Health Authorities
 [ADDRESS_986980] ....................................................................................... 46  
CR-6483, v 3.0  
Page 3 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
13.6.  Reporting of Pr egnancy ........................................................................................ [ADDRESS_986981] KEEPI[INVESTIGATOR_1645]/ARCHIVING ................................ 48  
15.1.  Electronic Case Report Form/Data Collection ..................................................... 48  
15.2.  Trial Registration on Cl inicalTrials.gov ............................................................... 49  
16. DATA MANAGEMENT............................................................................................. 49  
16.1.  Access to Source Data/Document ........................................................................ 49  
16.2.  Confidentiality of Information.............................................................................. 49  
16.3.  Data Quality Assurance ........................................................................................ 50  
16.4.  Data Monitoring Committee (DMC) .................................................................... [ADDRESS_986982] (IEC/IRB) .......... [ADDRESS_986983] RETENTION................................................................................ 54  
20. FINANCIAL CONSIDERATIONS ............................................................................ 55  
21. PUBLICATION ........................................................................................................... 55  
22. REFERENCES ............................................................................................................ 55  
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) ..... 57  
APPENDIX B: PATIENT INSTRUCTION GUIDE ............................................................. 76  
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) ......................................... 77  
CR-6483, v 3.0  
Page 4 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX D:  ...................................... [ADDRESS_986984] Reported Ocular  Symptoms/Problems ..................................................... 87  
 Front and Back Surface Lens Deposit Grading Procedure ................................... 89  
 Determination of Distance Sphero cylindrical Refractive Error ............................ 94  
 Biomicroscopy Scale ........................................................................................... 100  
 Distance and Near Snellen Visual Acuity Evaluation ......................................... 106  
 Patient Reporte d Outcomes ................................................................................. 111  
 White Light Lens Surface Wettability ................................................................ 113  
APPENDIX E: IRIS COLOR SCALE ................................................................................. 115  
APPENDIX F: STARTING LENS POWER GUIDANCE .................................................. 116  
APPENDIX G: Guidelines for COVID-19 Risk Mitigation................................................. 117  
PROTOCOL COMPLIANCE INVESTI GATOR(S) SIGNATURE [CONTACT_1783] ........................ [ADDRESS_986985] OF TABLES
Table 1: Planned Enrollment by [CONTACT_402144] ..................................................................... 18  
Table 2: Duration of Study Visits ........................................................................................... 19  
Table 3: Test Articles ........................................................................................................ ...... 21  
Table 4: Ancillary Supplies ................................................................................................... . 21 
Table 5: Time and Events ...................................................................................................... . 24 
Table 6: Disallowed syst emic medications ............................................................................. 36  
Table 7: Disallowed syst emic antihistamines ......................................................................... 37  
Table 8: Examples of major and minor protocol deviations ................................................... [ADDRESS_986986] OF FIGURESFigure 1: Study Flowchart ..................................................................................................... . 13
 
CR-6483, v 3.0  
Page 5 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
SYNOPSIS 
Protocol Title Evaluation of marketed soft contact [CONTACT_722693], [ADDRESS_986987], Jacksonville, FL  [ZIP_CODE] 
Clinical Phase Clinical trial phase: Feasibility
Design control phase: Po st-market benchmark
Trial Registration This st udy will be registered on ClinicalTrials.gov by [CONTACT_71162](s) Inves tigational Products: none
Approved Products: Dailies Total 1
Wear and Replacement 
SchedulesWear Schedule: daily wear
Replacement Schedule: daily
Objectives Primary Objectives: This study is being conducted to evaluate 
the clinical performance of a marketed product.
Study Endpoints Primary endpoint(s): CLUE overall comfort and vision. 
Other observations: Subjective responses concentrated on 
other aspects of vision, co mfort, and/or handling. 
Study Design This is a bilateral, 2-week dispensing, non-randomized, 
controlled, single-masked, single-arm study.  Each subject 
will be bilatera lly fitted with the study lens.  
There will be a total of 2 visits:
1. Visit 1: Screening, baselin e evaluation and lens fitting. 
2. Visit 2: Follow-up evaluation and final evaluation.  See the flow chart at the end of the synopsis table for the 
schematic of the study visits  and procedures of main 
observations (
Figure 1).
Sample Size Up to [ADDRESS_986988] lenses, daily  wear reusable and daily 
disposable.  Subjects may be of any race or ethnicity that meet the eligibility criteria.
CR-6483, v 3.0  
Page 9 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Eligibility Criteria - 
Inclusion Potential subjects must satisfy all of the following criteria to be enrolled in the study: 
Inclusion Criteria following Screening The subject must: 1. Read, understand, and sign the STATEMENT OF 
INFORMED CONSENT and receive a fully executed 
copy of the form. 
2. Appear able and willing to adhere to the instructions set 
forth in this clinical protocol.
3. Be between 18 and 39 (inclusive) years of age at the time 
of screening. 
4. By [CONTACT_6270]-report, habitually wear spherical soft silicone 
hydrogel contact [CONTACT_35482] a daily wear or daily disposable wear modality (i.e., not extended wear modality). Habitual wear is defined as a minimum of [ADDRESS_986989]â€™s vertex-corrected 
distance refraction must be between -1.00 and -6.00 DS 
(inclusive) in each eye.
8. The magnitude of the cylindrical component of the 
subjectâ€™s vertex-corrected distance refraction must be between 0.00 and 1.00 DC (inclusive) in each eye. 
9. The best corrected, monocular, distance visual acuity 
must be 20/25or better in each eye. 
CR-6483, v 3.0  
Page 10 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Eligibility Criteria â€“ 
Exclusion Potential subjects who meet any of the following criteria will be excluded from participating in the study: 
Exclusion Criteria following Screening
The subject must not: 1. Be currently pregnant or lactating. 
2. Be currently using any ocul ar medications or have any 
ocular infection of any type. 
3. By [CONTACT_6270]-report, have any oc ular or systemic disease, 
allergies, infection, or use of medication that the investigator believes might contraindicate or interfere 
with contact [CONTACT_13279], or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g., rheumatoid arthritis, SjÃ¶grenâ€™s syndrome), or history of serious mental illness or 
seizures. See Section 9.[ADDRESS_986990] habitually worn rigi d gas permeable (RGP) lenses, 
orthokeratology lenses, or hybrid lenses (e.g.,SynergEyes, SoftPerm) within the past [ADDRESS_986991] 
clinical trial within 30 da ys prior to study enrollment. 
8. Be an employee (e.g., Investigator, Coordinator, 
Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of 
the clinical site.
Exclusion Criteria at Baseline Evaluation
The subject must not: 9. Have clinically significant (grade 3 or higher on the FDA 
grading scale) slit lamp findings (e.g., corneal edema, 
neovascularization or stai ning, tarsal abnormalities or 
bulbar injection) or other co rneal or ocular disease or 
abnormalities that the inve stigator believes might 
contraindicate contact [CONTACT_163066] (including entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], chalazia, recurrent st yes, glaucoma, history of 
CR-6483, v 3.0  
Page 11 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
recurrent corneal erosions, aphakia, moderate or above 
corneal distortion, herpetic ke ratitis). (Specify method of 
determination if needed).
10. Have a history of strabismus or amblyopia. 11. Have fluctuations in vision due to clinically significant 
dry eye or other ocular conditions.  
12. Have had or have planned (within the study period) any 
ocular or intraocular surg ery (e.g., radial keratotomy, 
PRK, LASIK, iridotomy, re tinal laser photocoagulation, 
etc.).
Disallowed Medications/Interventions  No ocular medications. 
See Section 9.1 for details re garding disallowed systemic 
medications.
Measurements and 
ProceduresSubjects will respond to a GSI/MRD questionnaire. 
Microbiology or Other Laboratory Testing None 
Study Termination The occurrence of an Unanticipated Adverse Device Effect 
(UADE) or Serious Adverse Event (SAE) for which a causal relationship to a test article ca nnot be ruled out, will result in 
stoppi[INVESTIGATOR_35434]. In the 
event of a UADE or SAE, the Sponsor Medical Monitor may unmask the treatment regimen of  subject(s) and may discuss 
this with the Principal Investigator [INVESTIGATOR_35435].
Ancillary Supplies/ Study-Specific MaterialsRevitaLens, preservative-free artificial tears.
Principal Investigator(s) and Study Institution(s)/Site(s)A full list of Principal Investigators, clinical sites, and institutions is kept separately from the St udy Protocol and is 
included in the study Trial Master File.
CR-6483, v 3.0  
Page 12 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF 
TERMS
ADE   Adverse Device Effect
ADHD   Attention Deficit Hyperactivity DisorderAE   Adverse Event/Adverse ExperienceBSCVA  Best Spectacle Corrected Visual AcuityCFR   Code of Federal Regulations CLUE   Contact [CONTACT_722694]
   
D   Diopter DMC   Data Monitoring CommitteeeCRF   Electronic Case Report FormEDC   Electronic Data CaptureETDRS  Early Treatment Diabetic Retinopathy Study
FDA   Food and Drug Administration GCP   Good Clinical PracticeHEV   High Energy Visible light HIPAA  Health Insurance Portability and Accountability Act HIV   Human Immunodeficiency Virus IB   Investigatorâ€™s Brochure ICH   The International Council for Harmonization IDE   Investigational Device Exemption IEC   Independent Ethics Committee IRB   Institutional Review BoardISO   International Organization for Standardization ITT   Intent-to-TreatJJVC   [COMPANY_012] Vision Care, Inc. LASIK   Laser-Assisted in Situ KeratomileusisLogMAR  Logarithm of Minimal Angle of Resolution OD   Right Eye OS   Left EyeOU   Both Eyes PIG   Patient Instruction Guide PQC   Product Qu ality Complaint 
PRK   Photorefractive KeratectomyPRO   Patient Reported Outcome QA   Quality Assurance SAE   Serious Adverse Event/Serious Adverse Experience SAP   Statistical Analysis PlanSAS   Statistical Analysis SystemSD   Standard Deviation 
CR-6483, v 3.0  
Page 14 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
UADE   Unanticipated Adverse Device Effect
UV   Ultraviolet radiation[LOCATION_003]DE  Unanticipated Serious Adverse Device EffectVA   Visual Acuity
1. INTRODUCTION AND BACKGROUND
This study will investigate the clinical performance of a marketed contact [CONTACT_13293].
1.1. Name [CONTACT_722699] 1 (DT1) is a marketed product.  Fu rther details about the test articles are found 
in section [ADDRESS_986992] 6 
hours per day and 5 days per week  for approximately two weeks.
1.3. Summary of Findings fr om Nonclinical Studies
Not Applicable â€“ Marketed product only. 
1.4. Summary of Known Risks and Benefits to Human Subjects
The risks of wearing soft contact [CONTACT_722695]. Benefits to the subjects include the 
correction of their refractive error.
For the most comprehensive risk and benefit information regarding DT1, refer to the latest 
version of the package insert of the marketed product.
1.5. Relevant Literature References and Prio r Clinical Data Relevant to Proposed 
Clinical Study
The package insert for the DT1 Study lens can be found in the appendices.  Prior clinical data 
of the investigational lens is summari zed in the Investigatorâ€™s Brochure. 
Articles that pertain to the DT1 lenses exist with a sampling shown here: 
1. Wolffsohn, James, et al. "The influen ce of end of day s ilicone hydrogel daily 
disposable contact [CONTACT_163069], physiology a nd lens wettability." 
Contact [CONTACT_163071] 38.5 (2015): 339-344. 
2. Dumbleton, Kathryn A., et al. "A multi-c ountry assessment of compliance with daily 
disposable contact [CONTACT_13293] w ear." Contact [CONTACT_163071] 36.6 (2013): 304-312. 
3. Jayasree, Stephy VK, et al. "Quantifica tion of water content in contact [CONTACT_722696]." 2021 46th 
International Conference on Infrared, Mi llimeter and Terahertz Waves (IRMMW-
THz). IEEE.
CR-6483, v 3.0  
Page 15 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
4.0RQWpVá€¨0LFy5REHUWHWDO2Qá€¨H\HRSWLFDOTXDOLW\RIGDLO\GL VSRVDEOHFRQWDFWOHQVHV
for different wearing times." Ophthalmic  and Physiological Optics 33.5 (2013): 581-
591.
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES
2.1. Objectives 
Primary Objective: 
This study is being conducted to evaluate the clinical perform ance of a marketed product. 
2.2. Endpoints 
Primary Endpoints : 
xCLUE overall comfort 
xCLUE overall vision 
Subjective overall comfort and vision will be assessed using Contact [CONTACT_169754] (CLUE) questionnaire at the two-week follo w-up. CLUE is a validated patient-reported 
outcomes questionnaire to  assess patient-experience attributes  of soft, disposable contact 
[CONTACT_13276] (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal 
distribution with a population average score of 60 (SD 20), where higher scores indicate a more 
favorable/positive response. A 5-point increase in an average CLUE score translates into 10% shift in the distribution of scores for populati on of soft disposable contact [CONTACT_19554].
5
Other Exploratory Endpoint(s):Subjective responses concentrat ed on other aspects of vision, comfort, and/or handling. 
2.3. Hypotheses
No statistical hypotheses will be  tested. All study endpoints will be summarized by [CONTACT_84814].   
3. TARGETED STUDY POPULATION
3.1. General Characteristics 
Approximately [ADDRESS_986993] lenses worn as daily wear reusable 
or daily disposable.  All subjects will be the age of t18 and <40.  Subjects will wear the study 
contact [CONTACT_722697] a daily wear (DW) daily disposable (DD) 
basis for a total study duration of approxima tely 14 days (2 weeks) per subject.  
CR-6483, v 3.0  
Page 16 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
3.2. Inclusion Criteria
Potential subjects must satisfy all of the fo llowing criteria to be enrolled in the study: 
Inclusion Criteria after Screening
The subject must: 
1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and 
receive a fully executed copy of the form.
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
3. Be between 18 and 39 (inc lusive) years of age at the time of screening. 
4. By [CONTACT_6270]-report, habitually wear spherical soft silicone hydrogel c ontact lenses in both 
eyes in a daily wear or daily disposable wear modality (i.e., not extended wear modality). Habitual wear is defined as a minimum of [ADDRESS_986994]â€™s vertex-corrected distance refraction must be 
between -1.00 and -6.00 DS (inclusive) in each eye. 
8. The magnitude of the cylindrical component of the subjectâ€™s vertex -corrected distance 
refraction must be between 0.00 and 1.00 DC (inclusive) in each eye. 
9. The best corrected, monocular, distance visual acuity must be 20/25 or better in each 
eye.
3.3. Exclusion Criteria
Potential subjects who meet any of the following criteria will be excluded from participating in the study: 
Exclusion Criteria following Screening:
The subject must not: 
1. Be currently pregnant or lactating. 
2. Be currently using any ocular medications or have any ocular in fection of any type. 
3. By [CONTACT_6270]-report, have any ocul ar or systemic disease, alle rgies, infection, or use of 
medication that the investig ator believes might contrai ndicate or interfere with 
contact [CONTACT_13279], or otherwise compro mise study endpoints, including infectious 
disease (e.g., hepatitis, tuberculosis), c ontagious immunosuppressive disease (e.g., 
Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g., rheumatoid 
arthritis, SjÃ¶grenâ€™s syndrome), or history of  serious mental illness or seizures. See 
Section 9.[ADDRESS_986995] habitually worn rigid gas permeable  (RGP) lenses, orthokeratology lenses, or 
hybrid lenses (e.g., SynergEyes, Soft Perm) within the past [ADDRESS_986996] lenses. 
CR-6483, v 3.0  
Page 17 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
5. TEST ARTICLE ALLOCATION AND MASKING
5.1. Test Article Allocation 
Use of the study article will be non-randomized.  All subjects will  receive the same study lens 
on both eyes. 
The following must have occurred prior to lens fitting: 
Í»Informed consent must have been obtained. 
Í»The subject must have met all eligibility criteria.
Í»The subjectâ€™s screening and baseline info rmation must have been collected.
When dispensing test articles, the following steps should be followed: 
1. Investigator or designee (documented on the Delegation Log) will consult the lens 
fitting schedule to obtain the test article assignment for that subject prior to dispensing. 
2. Investigator or designee will record the subjectâ€™s number on the appropriate line of the 
lens fitting schedule. 
3. Investigator or designee will pull the appr opriate test articles from the study supply. 
All test articles that are opened, whether dispensed (placed/fit on eye or dispensed 
outside the clinical site) or not, must be recorded on the Test Article Accountability 
Log in the â€œDispensedâ€ section. 
5.2. Masking
This is a single-masked trial. All subjects will be assigned to the same study lenses in this single arm study. Subjects will be unaware of the identity of the study lenses.  Investigators 
and clinical site personnel invol ved in the data collection will not be masked as to the identity 
of the study lenses.  
5.3. Procedures for Maintainin g and Breaking the Masking
The identity of the study lenses will be masked to the subjects by [CONTACT_703881]. The label will contain the study  number, lot number, sphere power, expi[INVESTIGATOR_703860].  
Under normal circumstances, the mask should not be broken until all subj ects have completed 
the study and the database is finalized. Otherwise, the mask s hould be broken only if specific 
emergency treatment/course of ac tion would be dictated by [CONTACT_35496]. In such cases, the investigator may, in  an emergency, contact [CONTACT_7195]. In 
the event the mask is broken, the sponsor must be informed as soon as possible. The date, time, 
and reason for the unmasking must be documented in the subject record. 
Subjects who have had their tr eatment assignment unmasked are expected to return for all 
remaining scheduled evaluations. Subjects who are discontinued will be replaced. 
CR-6483, v 3.0  
Page 20 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
6.3. Administration of Test Articles
Study articles will be disp ensed to subjects meeting all eligibility requirements, including any 
dispensing requirements set forth in this clinical protocol. Subjects will be dispensed an 
adequate supply of test  articles to complete the study.  Lost or damaged test articles may be
replaced at the discretion of the investigator and/or the sponsor.   
6.4. Packaging and Labeling
The study articles will be packaged in blisters as the primary packaging. The study article will 
be over-labeled to mask the identity of the lens .  The study articles will be in plastic bags as 
the secondary packaging form.  The sample study label is shown below. The information 
represented on the label below is sample information only and is not representative of the actual study lens information. 
Primary Packaging Secondary Packaging
6.5. Storage Conditions 
Test articles will be maintained at ambient temperatures at the clinical site. Test articles must be kept under secure conditions. 
6.6. Collection and St orage of Samples 
No samples will be collected as  part of the study procedures. 
When possible, any lens or test article associated with an Adverse Event and/or a Product Quality Complaint must be retained and stored in a glass vial with moderate solution pending directions from the sponsor for potential return to JJVC. 
6.7. Accountability of Test Articles
JJVC will provide the Investigator with suffici ent quantities of study ar ticles and supplies to 
complete the investigation. The I nvestigator is asked to retain all lens shipment documentation 
for the test article accountability records. 
CR-6483, v 3.0  
Page 22 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Test articles must be ke pt in a locked storage cabinet, accessible only to those assigned by [CONTACT_35500]. The Investigator may delegate this activity to  authorized study site 
personnel listed on the Site Dele gation Log. All test articles mu st be accounted. This includes:
1. What was dispensed for the subject for trial fitting, to wear out of the office, or issued 
for the subject to replace appropriately between visits.  
2. What was returned to the Investigator  unused, including expi[INVESTIGATOR_93785].
3. The number and reason for unplanned replacements. 
The Investigator will collect all unused test article s from the subjects at the end of the subjectâ€™s 
participation. Subject returned unused test articles must be se parated from the clinical study 
inventory of un-dispensed test articles and must be labeled with the subject number and date 
of return. Following final reconciliation of test articles by [CONTACT_2037], the Investigator or 
monitor will return all unus ed test articles to JJVC .
If there is a discrepancy between the shipment  documents and the contents, contact [CONTACT_35501] .
Reference : Site Instructions for Test Article Receipt and Test Article Accountability for additional information. 
7. STUDY EVALUATIONS 
7.1. Time and Event Schedule
CR-6483, v 3.0  
Page 23 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xSubject not compliant to protocol such as study lens wear time or habitual lens wear 
while enrolled in the study. 
xSubject lost to follow-up. 
xSubject no longer meets eligibility criteri a (e.g. the subject becomes pregnant). 
xSubject develops significant or serious adverse events necessitating discontinuation of 
study lens wear. 
xSubjects who have experienced a Corneal Infiltrative Event (CIE). 
xInvestigatorâ€™s clinical judgment regarding the subject safety reasons (that it is in the 
best interest of the subject to stop treatment).
xSubject missed a study visit . 
xSubject not compliant with study lens wear schedule (i.e., wears study lenses less than 
at least [ADDRESS_986997] 5 da ys a week over the 2-week wear period)
xSubject not successfully dispensed due to lack of efficacy and safety including poor 
vision, poor comfort or unacceptable fit. 
For discontinued subjects, the Investigator will: 
xComplete the current visit (scheduled or unscheduled). 
xComplete the Final Evaluation, indicating th e reason that the subject was discontinued 
from the study. 
xRecord the spherocylindrical refraction with  best corrected distance visual acuity. 
xCollect used test article(s) (worn or brought to the visit) from the subject and discard 
them, unless otherwise stated in Section 7.2.
xCollect all unused test article(s) from the subject. 
xMake arrangements for subject care, if needed, due to their study participation 
Additional subjects will be enrolled if a subj ect discontinues from the study prematurely.  
In cases where a subject is lost to follow-up, ever y possible effort must be made to contact [CONTACT_35508]/withdrawal. The measures taken to follow 
up must be documented including two written attempts and a certified letter (or equivalent) as the final attempt. 
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION
Concomitant medications will be  documented during screening and updated during the study.  
xDisallowed medications for this study include : medications that may interfere with 
contact [CONTACT_13279] (see Section 9.1).  Habitu al medications used by [CONTACT_163079].
xConcomitant therapi[INVESTIGATOR_35443]: NA
CR-6483, v 3.0  
Page 35 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
JJVC reserves the right to terminate the study at any time for any reason. Additionally, the 
IEC/IRB reserves the right to terminate the study if an unreasonable risk is determined. The 
study can be terminated by [CONTACT_35511], if in their opi[INVESTIGATOR_1649], after a discussion with JJVC, it is determined 
that it would be unwise to continue at the clinical site.
JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events. If it is 
determined that an adverse event presents an unr easonable risk, the investigation, or that part 
of the investigation presenting the risk, will be terminated as soon as possible. 
Should the study be terminated (either prematurely or as scheduled), the Investigator will notify the IEC/IRB and Regulatory Authority as  required by [CONTACT_35512]. 
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS
A Product Quality Complaint (PQC) refers to any written, electronic, or oral communication 
that alleges deficiencies related to the identity, quality, durability, reliability, safety,effectiveness or performance of test articles after they have been released for clinical trial use.  
Potential complaints may come from a variety of sources including but not limited to subjects, 
clinical research associates (CRA), clinical  operations managers (COM), medical monitors, 
and site personnel, etc. The following are not considered product quality complaints: 
xSubject satisfaction inquiries reported vi a â€œSubjective Questionna iresâ€ and â€œPatient 
Reported Outcomes (PRO).â€ 
xClinical test articles that are stored improperly or damaged after receipt at the investigational site.
xLens replacements that occur due to drops/fall-outs. 
xDamage deemed by [CONTACT_35513], 
and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where there is no deficiency alleged by [CONTACT_423]. 
Within [ADDRESS_986998] be 
recorded in the EDC system, which will trigger an automatic email notification to the appropriate COM/CRA and Clinical QA representative. In cases where the EDC system in use is not configured to send automatic notificati ons or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.   
Upon receipt of the EDC notification, the COM/ CRA will contact [CONTACT_19568]: 
xDate the complaint was received/recorde d in the EDC System (Date of Sponsor 
Awareness). 
xWho received the complaint. 
CR-6483, v 3.0  
Page 39 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xStudy number. 
xClinical site information (contact [CONTACT_2300], site ID, telephone number). 
xLot number(s). 
xUnique Subject Identifier(s). 
xIndication of who first observed co mplaint (site personnel or subject). 
xOD/OS indication, along with whet her the lens was inserted. 
xAny related AE number if applicable. 
xDetailed complaint description (scheduled/unscheduled visit, wear time, symptoms, 
resolution of symptoms, etc.). 
xEye Care Provider objective (slit lamp) findings if applicable. 
xConfirmation of product availa bility for return (and tracking information, if available), 
or rationale if product is not available for return (R efer to Form Control No. 
for test article return instructions).
Once a complaint is received, it will be assessed by [CONTACT_19569], CRA, or trained site personnel to determine if it is an Adverse Event/Seri ous Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or traine d site personnel will follo w Section 13 of this 
protocol. If the AE/SAE was potentially the result of a product quality related deficiency, these procedures also applies and will be executed in parallel.  
In some cases, a PQC form may be generated in EDC by [CONTACT_35514]. In this event, the 
PQC forms will be marked â€œIntentionally Left Bla nkâ€ or â€œILBâ€.  Justification for ILB must be 
documented. 
13. ADVERSE EVENTS
13.1. Definitions and Classifications 
Adverse Event (AE) â€“ An AE is â€œany untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to the investig ational medical device.â€  
Note : This definition includes events related to  the investigational medical device or the 
comparator, and to the procedures involved. Fo r users or other persons, this definition is 
restricted to events related to investigational medical devices.1
An AE includes any condition (including a pre-existing condition) that: 
1. Was not present prior to the study, but app eared or reappeared following initiation of 
the study. 
2. Was present prior to the study but worsen ed during the study. This would include any 
condition resulting from concomita nt illnesses, reactions to  concomitant medications, 
or progression of disease states.
CR-6483, v 3.0  
Page 40 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Note : Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immedi ately upon learning of the event. 
Serious Adverse Event (SAE) â€“ An SAE is any adverse event that led to any of the following: 
xDeath
xSerious deterioration in the health of the subject that resulted in any of the following: 
xLife-threatening illness or injury 
xPermanent or persistent impairment of a body structure or a body function 
xHospi[INVESTIGATOR_89620]-threatening illness or injury or 
permanent impairment to a body structure or a body function. 
xChronic disease 
xFoetal distress, foetal death or a congenital physical or mental impairment of birth 
defect.
Diagnoses and conditions that are considered Oc ular Serious Adverse Events include, but not 
limited to:
xMicrobial Keratitis (MK)
xIritis (including cells in the anterior chamber)
xPermanent decrease in best spectacle corrected visual acuity equivalent to 2 acuity lines 
or greater
xCentral Corneal Opacity
xCentral Corneal Neovascularization
xUveitis
xEndophthalmitis 
xHypopyon 
xHyphemia 
xPenetration of Bo wmanâ€™s Membrane 
xPersistent Epi[INVESTIGATOR_35449]  â€“ are defined as events that are symptomatic and warrant 
discontinuation (temporary or perman ent) of the contact [CONTACT_35515], but 
not limited to the following:
xContact [CONTACT_32985] (CLPU) 
xSignificant Infiltrative Events (SIE)
xSuperior Epi[INVESTIGATOR_19532] (SEALs)
xAny Temporary Loss of > 2 Lines of BSCVA 
xOther grade 3 or higher corneal findi ngs, such as abrasions or edema 
CR-6483, v 3.0  
Page 41 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xNon-contact [CONTACT_71176] - e.g. Epi[INVESTIGATOR_35450] (EKC) 
xAsymptomatic Corneal Scar
xAny corneal event which necessitates te mporary lens discontinuation > 2 weeks 
Non-Significant Adverse Events  â€“ are defined as those events that are usually asymptomatic 
and usually do not warrant discon tinuation of contact [CONTACT_35517] a reduction in 
wear time.  However, the Investigator may choos e to prescribe treatment as a precautionary 
measure.   
Diagnoses and conditions that are considered Ocular Non-Significant Adverse Events include, 
but not limited to the following:
xNon-significant Infiltrative Event (NSIE)
xContact [CONTACT_19573][INVESTIGATOR_19534] (CLPC)
xSuperficial Punctate Keratitis (SPK)
xConjunctivitis: Bacterial, Viral, Allergic
xBlepharitis
xMeibomianitis
xContact [CONTACT_35518], which necessitates temporary lens discontinuation < [ADDRESS_986999] (ADE) â€“ An ADE is an â€œadverse event related to the use of an 
investigational medical device.â€ 
Note 1: This definition includes adverse events resulting from insufficient or inadequate 
instructions for use, deployment, implantati on, installation, or opera tion, or any malfunction 
of the investigational medical device.
Note 2: This definition includes any event resulting from use error or from intentional misuse 
of the investigational medical device.[ADDRESS_987000] (UADE) â€“ A UADE is any serious adverse effect on 
health or safety or any life-threatening problem or death caused by, or associated with, the test 
article, if that effect, problem,  or death was not previously id entified in nature , severity, or 
degree of incidence in the investigational plan, Investigatorâ€™s Brochure or protocol, or any other unanticipated serious problem associated with the test article that relates to the rights, safety and welfare of subjects.
13.2. Assessing Adverse Events
In conjunction with the medical monitor, the Investigator will evaluate adverse events to ensure the events are categorized correctly. Elements of categorization will include: 
CR-6483, v 3.0  
Page 42 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xSeriousness/Classifications (s ee definition in Section 13.1). 
xCausality or Relatedness â€“ i.e., the relationship between the test article, study treatment 
or study procedures and the adverse event (not related, unlikely related, possibly 
related, or related - see definition in Section 13.2.1). 
xAdverse Event Severity â€“ Adverse event severity is used to assess the degree of intensity of the adverse event (mild, moderate, or severe - see definition in Section13.2.2). 
xOutcome â€“ not recovered or not resolved , recovering or resolving, recovered or 
resolved with sequelae, recovered or resolved, death related to adverse event, orunknown. 
xActions Taken â€“ none, temporar ily discontinued, permanently  discontinued, or other. 
13.2.1. Causality Assessment
Causality Assessment â€“ A determination of the relationship between an adverse event and the 
test article. The test article relationship for each adverse event should be determined by [CONTACT_19575]: 
xNot Related- An adverse event that is not re lated to the use of the test article, study 
treatment or study procedures. 
xUnlikely Related â€“ An adverse event for which an alternative explanation is more 
likely, e.g. concomitant treatme nt, concomitant disease(s), or the relationship of time 
suggests that a causal relationship is not likely. 
xPossibly Related â€“ An adverse event that might be  due to the use of the test article, or 
to the study treatment or study procedures. An alternative explanation, e.g. concomitant treatment, concomitant disease(s), is inconclusive. The relationship in time is reasonable. Therefore, the causal relationship cannot be excluded. 
xRelated â€“ An adverse event that is listed as a possible adverse effect (device) or adverse reaction (drug) and cannot be reasonably e xplained by [CONTACT_4867], e.g. 
concomitant treatment of concomitant disease(s). The relationship in time is very suggestive, e.g. it is confirmed by [INVESTIGATOR_5328]-challenge and re-challenge. 
13.2.2. Severity Assessment
Severity Assessment â€“ A qualitative assessment of the degree of intensity of an adverse event 
as determined by [CONTACT_19577]/her by [CONTACT_423]. The assessment of 
severity is made irrespective of  test article, study tr eatment or study procedure relationship or 
seriousness of the event and should be eval uated according to the following scale: 
xMild â€“ Event is noticeable to the subject but is easily tolerated and does not interfere with the subjectâ€™s daily activities.
xModerate â€“ Event is bothersome, possibl e requiring additiona l therapy, and may 
interfere with the subjectâ€™s daily activities.
xSevere â€“ Event is intolerable, necessitates additional ther apy or alterati on of therapy 
and interferes with the subjectâ€™s daily activities. 
CR-6483, v 3.0  
Page 43 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
13.3. Documentation and Follow-Up of Adverse Events
The recording and documenting of adverse even ts (ocular and non-ocular) begin when the 
subjects are exposed to the test article, study treatment or study proce dure. Adverse events 
reported before the use of test  article, start of st udy treatment, or study procedures will be 
recorded as medical history. However, if the c ondition deteriorates at any time during the study 
it will be recorded and reported as an AE. Untoward medical events reported after the subjectâ€™s 
exit from the study will be recorded as adverse ev ents at the discretion of the Investigator. 
Upon finding an adverse event, the Principal In vestigator will document the condition in the 
subject record and in the eCRFs and complete the Adverse Event eCRF.  
Complete descriptions of all adverse events must be available in the subject record. All 
Adverse Events including local and systemic re actions not meeting the criteria for â€œserious 
adverse eventsâ€ shall be captured on the appropriate case report form or electronic data system. All adverse events occurring while the subject  is enrolled in the study must be documented 
appropriately regardle ss of relationship.   
It is the Investigatorâ€™s responsibility to maintain documentation of each reported adverse event. All adverse events will be followed in accordance with applicable licensing requirements. Such 
documentation will include the following: 
xAdverse event (diagnosis not symptom). 
xDrawings or photographs (where appropri ate) that detail the finding (e.g., size,
location, and depth, etc.). 
xDate the clinical site was notified.
xDate and time of onset.
xDate and time of resolution.
xAdverse event classification, se verity, and relationship to te st articles, as applicable. 
xTreatment regimen instituted (where appropriate), including concomitant medications prescribed, in accordance with applicable licensing requirements. 
xAny referral to another hea lth care provider if needed. 
xOutcome, ocular damage (if any). 
xLikely etiology. 
xBest corrected visual acuity at the discovery of the ev ent and upon conclusion of the 
event, if the AE is related to the visual system.
Upon discovery of an AE that is deemed â€˜possibly relatedâ€™ or â€˜relatedâ€™ to the test article or 
study procedures (whether related to the visual  system or not), an AE review form ( ) 
must be completed. Additiona l dated and initialed entries should be made at follow-up 
evaluations. Separate forms must be completed for each eye if the AE is bilateral. 
In addition, if an infiltrate(s) is present, he/she  will complete the Corn eal Infiltrate Assessment 
eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the 
CR-6483, v 3.0  
Page 44 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
infection is microbial in nature. If cultures are collected, the date of culture collection and 
laboratory utilized will be recorded.  
Changes in the severity of an AE shall be documented to allo w an assessment of the duration 
of the event at each level of intensity to be performed. Adverse events characterized as 
intermittent require documentation of the onset and duration of each epi[INVESTIGATOR_1865]. Changes in the assessment of relationship to the Test Ar ticle shall also be clearly documented.
Subjects who present with an adverse event sh all be followed by [CONTACT_737], within 
licensure, until all signs and symptoms have retu rned to pre-treatment status, stabilized, or 
been satisfactorily resolved. If further treatme nt beyond licensure is required, the patient will 
be referred to the appropriate health care provider. The Investigator will use his/her clinical judgment as to whether a subject reporting with an adverse event will continue in the study. If a subject is discontinued from the study, it will be  the responsibility of the Investigator to 
record the reason for discontinuation. The Inves tigator will also document the adverse event 
appropriately and complete the Adverse Event eCRF. Any subjects with ongoing adverse events related to the test artic le, study treatment or study procedur es, as of the final study visit 
date, should be followed to resolution of the adve rse event or until referral to an appropriate 
health care provider, as recommended by [CONTACT_737]. Non-ocular adverse events that are not related to the test artic le, study treatment, or study proc edures may be recorded as 
â€œongoingâ€ without further follow-up. 
13.4. Reporting Adverse Events 
The Investigator will notify the Sponsor of an adverse event by e-mail, facsimile, or telephone 
as soon as possible and no later than 24 hours from discovery for any serious /significant 
adverse events, and 2 days from discovery for any non-significant adverse event. In addition, a written report will be submitted by [CONTACT_079] [INVESTIGATOR_35451]/IRB according to their requirements (Section 13.4.2) . The report will comment whether the adverse event was 
considered to be related to the test article, study tr eatment or study procedures. 
13.4.1. Reporting Adverse Events to Sponsor 
Serious/Significant Adverse Events
The Investigator will inform the sponsor of a ll serious/significant adve rse events occurring 
during the study period as soon as possible by e- mail or telephone, but no  later than [ADDRESS_987001] igator is obligated to pursue and obtain 
information requested by [CONTACT_35519]. All 
subjects experiencing a serious/s ignificant adverse event must be  followed up and all outcomes 
must be reported. 
When medically necessary, the Investigator ma y break the randomizati on code to determine 
the identity of the treatment that the subject received. The Sponsor and study monitor should 
be notified prior to unmas king the test articles. 
In the event of a serious/significant adverse event, the Investigator must: 
CR-6483, v 3.0  
Page 45 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xNotify the Sponsor immediately.
xObtain and maintain in the subjectâ€™s records all pertinent medical information and 
medical judgment for colleague s who assisted in the treatment and follow-up of the 
subject.
xProvide the Sponsor with a complete case history which includes a statement as to 
whether the event was or was not related to the use of the test article. 
xNotify the IEC/IRB as required by [CONTACT_35520] C/IRB reporting procedure according to 
national regulations. 
Unanticipated (Serious) Adverse Device Effect (UADE)In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigatorwill submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later 
than [ADDRESS_987002] report the results of the 
evaluation to FDA, the IEC/IRB and participati ng Investigators within [ADDRESS_987003]. 
Non-Serious Adverse EventsAll non-serious adverse events, including non-seri ous adverse device effects, will be reported 
to the sponsor by [CONTACT_35521] 2 days from discovery. 
13.4.2. Reporting Adverse Events to the Resp onsible IEC/IRB and Health Authorities
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRBâ€™s written guidelines. Each clinical site will refer to and follow any guidelines set forth by [CONTACT_19581]/IRB. Each clinical site wi ll refer to and follow any guidelines set forth 
by [CONTACT_19582]. 
The Sponsor will report applicable Adverse Events to the local health authorities according the 
written guidelines, including reporting timelines.  
13.5. Event of Special Interest
None 
13.6. Reporting of Pregnancy
Subjects reporting pregnancy (by [CONTACT_6270]-report) during the study will be discontinued after the event is recorded as an Adverse Event. Once  discontinued, pregnant participants and their 
fetuses will not be monitored for study related purposes. Pregnant participants are not 
discontinued from contact [CONTACT_19583], but due to 
general concerns relating to pre gnancy and contact [CONTACT_19584]. Sp ecifically, pregnant women are 
discontinued due to fluctuations in refractive error and/or visual  acuity that occur secondary to 
systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus. 
CR-6483, v 3.0  
Page 46 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
14. STATISTICAL METHODS
14.1. General Considerations
Statistical analysis will be undertaken by [CONTACT_941] s ponsor or under the authority of the sponsor. A 
general description of the statistical methods to be  implemented in this c linical trial is outlined 
below.
All data summaries and statistical analyses will be performed using the SAS software Version
9.4 or higher (SAS Institute, Cary, NC).6Throughout the analysis of data, the results for each 
subject/eye will be used when available for summarization and statistical analysis. Unscheduled visits will be  summarized separately.
Summary tables (descriptive statistics and/or frequency tables) will be provided for all baseline variables, efficacy variables and safety variable s as appropriate. Continuous variables will be 
summarized with descriptive statistics (n, mean, standard deviation (SD), median, minimum and maximum). Frequency count and percentage of subjects or eyes within each category will 
be provided for categorical data.
14.2. Sample Size Justification
The target is to enroll approximately 80 eligible subjects with 70 subjects to complete the study. There is no statistical hypothesis to be te sted. Targeting 70 subjects to complete the 
study will be sufficient to evaluate descriptiv e summaries of the primary endpoints and other 
observations. The data collected from this clinical trial will be utilized for sample size calculations for future clinical trials.
14.3. Analysis Populations 
Safety Population: All subjects who are administered any test ar ticle excluding subjects who drop out prior to 
administering any test article. At least one observation should be recorded. 
Per-Protocol Population:  
All subjects who successfully complete all visits and do not substantially deviate from the protocol as determined by [CONTACT_3433] e trial cohort review committee pr ior to database hard lock. 
Justification for the exclusion of subjects with protocol de viations from the per-protocol 
population set will be documen ted in a memo to file. 
14.4. Level of Statis tical Significance
Not applicable. No statistical testing will be performed.
14.5. Primary Analyses
Descriptive summary statistics (e .g., mean, median, and standard de viation) will be calculated 
for each primary endpoint by [CONTACT_11191] (baseline and follow-up). No sta tistical hypothesis will 
be tested on the primary endpoints. 
CR-6483, v 3.0  
Page 47 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
14.6. Secondary Analyses  
Not applicable 
14.7. Other Exploratory Analysis  
All other observations will be summarized descriptively by [CONTACT_11191].
14.8. Interim Analysis  
An interim analysis will be performed after approximately 90% of the subjects (about 63 
subjects) complete the study. The interim an alysis will consist of subject accountability, 
demographics, and descriptive summaries for questionnaire data. The results will be reviewed 
to gain insights of the DT1 lens performance before the competitive claim study is initiated. 
The results will be communicated to the project team.
14.9. Procedure for Handling Mi ssing Data and Drop-Outs
Missing or spurious values will not be imputed. The count of mi ssing values will be included 
in the summary tables and listings. 
14.10. Procedure for Reporting Deviations from Statistical Plan 
The analysis will be conducted according to that specified in above sections. There are no known reasons for which it is planned to deviate fr om these analysis methods. If for any reason 
a change is made, the change will be documented in the study re port along with a justification 
for the change.
15. DATA HANDLING AND RECORD KEEPI[INVESTIGATOR_1645]/ARCHIVING
15.1. Electronic Case Report Form/Data Collection
The data for this study will be captured on electronic case report forms (eCRFs) using the 
BioClinica EDC system. An authorized data orig inator will enter study data into the eCRFs 
using the EDC system. Data collected on equipm ent that is not captured in EDC will be 
formatted to the specification of the JJVC databa se manager and sent to JJVC for analysis.  
External data sources for this study include:  Not Applicable .
The clinical data will be recorded on dedicated eCRFs specifically designed to match the study procedures for each visit. Only specifically delegated staff can enter data on a CRF.  Once 
completed, the eCRFs will be reviewed for accuracy and completeness and signed by [CONTACT_737]. The sponsor or sponsorâ€™s representa tives will be authorized to gain access to the 
subject recordation for the purposes of  monitoring and auditing the study.  
Edit checks, electronic queries, and audit trails are built into the system to ensure accurate and complete data collection. Data w ill be transmitted from the clini cal site to a secure central 
database as forms are completed or updated, ensuring information accuracy, security, and 
CR-6483, v 3.0  
Page 48 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
confidentiality. After the final database lock, the Investigator will be provided with Individual 
Patient Profiles (IPP) including the full audit trail on electronic media in PDF format for all of the study data. The IPP must be retained in the study files as a certified copy of the source data 
for the study.  
The content and structure of the eCRFs are compliant with ISO14155:2020.
0Subject Record
At a minimum, subject record should be available for the following:  
xsubject identification
xeligibility
xstudy identification
xstudy discussion 
xprovision of and date of informed consent 
xvisit dates
xresults of safety and efficacy para meters as required by [CONTACT_89633]-up of adverse events 
xmedical history and concomitant medication
xtest article receipt/dispensing/return records
xdate of study completion 
xreason for early discontinuation of test article or withdrawal from the study, if 
applicable
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. The first point of  entry is considered to be the source record. 
Adverse event notes must be reviewed and initialed by [CONTACT_737]. 
15.2. Trial Registration on ClinicalTrials.gov  
This study will be registered on ClinicalTrials.gov by [CONTACT_1034]. 
16. DATA MANAGEMENT
16.1. Access to Source Data/Document
The Investigator/Institution will permit trial-rela ted monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by [CONTACT_20618]/documents. Should the 
clinical site be contact[CONTACT_35527]/IRB or regulatory authority, JJVC must be 
contact[CONTACT_35528] [ADDRESS_987004] and pa tent application pro cesses, scientific 
data or other pertinent inform ation is confidential and rema ins the property of JJVC. The 
Investigator may use this information for the purposes of the study only. It is understood by 
[CONTACT_240316]-6483, v 3.0  
Page 49 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
the Investigator that JJVC will use information developed in this clinical study in connection 
with the development of the investigational product a nd therefore may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the information derived from this clinical study, the Investigator understands  that he/she has an 
obligation to provide complete test results and all data developed during this study to the 
Sponsor. 
16.3. Data Quality Assurance 
Steps will be taken to ensure the accuracy and reliability of data, include the selection of 
qualified investigators a nd appropriate clinical sites and review of protocol procedures with 
the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub-Investigators and clinical site  personnel are familiar with the pr otocol and all study-specific 
procedures and have appropriate  knowledge of the study article. 
Training on case report form comp letion will be provided to clini cal site personnel before the 
start of the study. The Sponsor will review case  report forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring visits, and after transmission to 
data management. Any data discrepancies will be resolved with the Investigator or designee, as appropriate.
Quality Assurance representatives from JJVC may visit clinical sites to review data produced 
during the study and to access compliance with applicable regulations pertaining to the conduct of clinical trials. The clinical sites will provide direct access to study-related source data/documents and reports for the purpose of monitoring and auditing by [CONTACT_35529]. 
16.4. Data Monitoring Committee (DMC) 
Not applicable 
17. CLINICAL MONITORING
The study monitors will maintain close contact  [CONTACT_35530] [INVESTIGATOR_35453]â€™s designated clinical site personnel. The monitorâ€™s responsibilities will include:
xEnsuring that the investigation is being conducted according to the protocol, any 
subsequent versions, and regulat ory requirements are maintained. 
xEnsuring the rights and wellbei ng of subjects are protected. 
xEnsuring adequate resources, including fac ilities, laboratories, equipment, and 
qualified clinical site personnel.
xEnsuring that protocol deviations are doc umented with corrective action plans, as 
applicable. 
xEnsuring that the clinical site has sufficient test article and supplies. 
xClarifying questions regarding the study. 
xResolving study issues or problems that may arise. 
CR-6483, v 3.0  
Page 50 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
xReviewing of study records and source documentation verification in accordance with 
the monitoring plan. 
18. ETHICAL AND REGULATORY ASPECTS
18.1. Study-Specific Desi gn Considerations
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study, subjects will be given any new informati on that may affect their decision to continue 
participation. Subjects will be told that their consent to participate in the study is voluntary and 
may be withdrawn at any time with  no reason given and without pena lty or loss of benefits to 
which they would otherwise be entitled. Subjects will only be enrolled if the subject is fully able to understand the risks, be nefits, and potential adverse events of the study and provide
their consent voluntarily. 
18.2. Investigator Responsibility 
The Principal Investigator [INVESTIGATOR_35454], the investigational plan, section 4 of the ICH E6(R2)guidelines on Good Clinical Practice (GCP),
0and applicable regulatory requirements. GCP is 
an international ethical and sc ientific quality standard for designing, conducting, recording, 
and reporting studies that involve the particip ation of human subjects. Compliance with this 
standard provides public assurance that the right s, safety, and well-bei ng of study subjects are 
protected, consistent with the principl es of the Declaration of Helsinki 64thWMA General 
Assembly 20130and that the clinical study data are credible. The Investigator must maintain
clinical study files in accordance with Section 8  of the ICH E6(R2) guidelines on Good Clinical 
Practice (GCP)0, and applicable regul atory requirements. 
18.3. Independent Ethics Comm ittee or Institutional Review Board (IEC/IRB)
Before the start of the study, the Investigator (or Sponsor when applicable) will provide the IEC/IRB with current and complete copi[INVESTIGATOR_35455] (where applicable): 
xFinal protocol. 
xSponsor-approved informed consent form (a nd any other written materials to be 
provided to the subjects) 
xInvestigatorâ€™s Brochure (o r equivalent information). 
xSponsor-approved subject r ecruitment materials. 
xInformation on compensation for study-relate d injuries or payment to subjects for 
participation in the study. 
xInvestigatorâ€™s curriculum vitae, clinical lic enses, or equivalent information (unless not 
required, as documented by [CONTACT_8134]/IRB). 
xInformation regarding funding, name [CONTACT_35596] e Sponsor, institutiona l affiliations, other 
potential conflicts of interest, and incentives for subjects. 
xAny other documents that the IEC/IRB requests to fulfill its obligation. 
CR-6483, v 3.0  
Page 51 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
This study will be undertaken only after IEC/IRB has given full approval of  the final protocol,
the informed consent form, applicable recruiting materials, and subject compensation 
programs, and the Sponsor has received a copy of  this approval. This approval letter must be 
dated and must clearly identify the documents being approved. 
During the study, the Investigator (or Sponsor  when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate: 
xProtocol revisions 
xRevision(s) to informed consent form and any other written materials to be provided to subjects
xIf applicable, new or revise d subject recruitment materi als approved by [CONTACT_89634]-relate d injuries or payment to subjects for 
participation in the study 
xInvestigatorâ€™s Brochure revisions  
xSummaries of the status of the study (at leas t annually or at intervals stipulated in 
guidelines of the IEC/IRB) 
xReports of adverse events that are serious, unanticipated, and associated with the test articles, according to the IRBâ€™s requirements
xNew information that may adversely affect th e safety of the subjects or the conduct of 
the study 
xMajor protocol deviations as required by [CONTACT_6179]/IRB 
xReport of deaths of subjects under the Investigator's care 
xNotification if a new Investigator is responsible for the study at the clinical site
xAny other requirements of the IEC/IRB 
For protocol revisions that incr ease subject risk, the revisions a nd applicable informed consent 
form revisions must be submitted promptly to the IEC/IRB for review and approval before implementation of the change(s). 
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request 
should be documented in writing. At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB 
about the study completion. Documentation of this no tification must be retained at the clinical 
site and a copy provided to the CRO or Sponsor as applicable. 
18.4. Informed Consent
Each subject or their representative, must give written consent according to local requirements after the nature of the study has been fully explained. The consent form must be signed before performance of any study-related activity. The cons ent form that is used must be approved by 
[CONTACT_19597]/IRB. Th e informed consent is in accordance with 
principles that originated in the Declaration of Helsinki
0current ICH GCP0Error! Reference source not 
found.and ISO [ZIP_CODE]:[ZIP_CODE] guidelines, applicable regulatory requirements, and Sponsor Policy.
CR-6483, v 3.0  
Page 52 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Before entry into the study, the Investigator or an authorized member of the clinical site 
personnel must explain to potential subject the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study, and any discomfort it may entail. Subjects will be informed 
that their participation is voluntary and that they may withdraw consent to participate at any time. 
The subject will be given sufficient time to read  the informed consent form and the opportunity 
to ask questions. After this explanation and before entry into the study, consent should be 
appropriately recorded by [CONTACT_722698]'s dated signature. After having obtained the 
consent, a copy of the informed consen t form must be given to the subject. 
18.5. Privacy of Personal Data 
The collection, processing and disclosure of pers onal data and medical information related to 
the Study Subject, and personal data  related to Principal Investig ator and any clinical site 
personnel (e.g., name, clinic addr ess and phone number, curriculum vitae) is subject to 
compliance with the Health Information Port ability and Accountability Act (HIPAA) and other
applicable personal data protection and security laws and regulations.
7,8Appropriate measures 
will be employed to safeguard these data, to maintain the confidentiality of the personâ€™s related health and medical information, to properly info rm the concerned persons about the collection 
and processing of their personal data, to grant them reasonable access to their personal data 
and to prevent access by [CONTACT_35532]. 
All information obtained during the course of the investigation will be regarded as confidential. 
All personal data gathered in this trial will be treated in strictest confidence by [CONTACT_4718], 
monitors, Sponsorâ€™s personnel and IEC/IRB. No data will be disclose d to any third party 
without the express permission of the subject  concerned, with the exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulat ory organizations in the context of their 
investigation related ac tivities that, as part of the inves tigation will have access to the CRFs 
and subject records. 
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary to investigate the efficacy, safety, quality, and utility of 
the investigational product( s) used in this study. 
These data must be collected and processed with adequate precauti ons to ensure confidentiality 
and compliance with applicable data pr ivacy protection laws and regulations. 
The Sponsor ensures that the personal data will be: 
xprocessed fairly and lawfully. 
xcollected for specified, explicit, and legitimate purposes and not further processed in a way incompatible with these purposes. 
xadequate, relevant, and not excessive in relation to said purposes. 
xaccurate and, where necessary, kept current. 
CR-6483, v 3.0  
Page 53 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
Explicit consent for the processing of personal data will be obtained from the participating 
subject before collection of data . Such consent should also addre ss the transfer of the data to 
other entities and to other countries. 
The subject has the right to request through the Investigator access to hi s personal data and the 
right to request rectification of  any data that are not correct or complete. Reasonable steps 
should be taken to respond to such  a request, taking into considera tion the nature of the request, 
the conditions of the study, and the applicable laws and regulations. 
Appropriate technical and orga nizational measures to protec t the personal data against 
unauthorized disclosures or acces s, accidental or unlawful destruction, or accidental loss or 
alteration must be put in place. Sponsor pe rsonnel whose responsibilities require access to 
personal data agree to keep the id entity of study subjects confidential. 
19. STUDY RECORD RETENTION
In compliance with the ICH GCP guidelines0, the Investigator/Institution will maintain all 
CRFs and all subject records that support the data  collected from each subject, as well as all 
study documents as specified in ICH GCP0and all study documents as specified by [CONTACT_12926](s). The Investigator/Institution will take measures to prevent 
accidental or premature destruction of these documents.
Essential documents must be retained until at least two (2) years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or until at least two (2) years have elapsed since the formal discontinuation of clin ical development of the i nvestigational product. These 
documents will be retained for a longer peri od if required by [CONTACT_35533]. It is the responsibility of the Sponsor to inform the Investigator/Institution as to when these documents no longer need to be retained. 
If the responsible Investigator retires, relocat es, or for other reasons withdraws from the 
responsibility of keepi[INVESTIGATOR_8090], custody must be transferred to a person who will accept the responsibility. The Sponsor must be no tified in writing of the name [CONTACT_19619]. Under no circumstance shall the Investigator relocate or dispose of any 
study documents before having obtaine d written approval from the Sponsor. 
If it becomes necessary for the Sponsor or the ap propriate regulatory auth ority to review any 
documentation relating to this study, the Investig ator must permit access to such reports.  
If the Investigator has a question regarding rete ntion of study records, he/she should contact 
[CONTACT_19599].
CR-6483, v 3.0  
Page 54 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
20. FINANCIAL CONSIDERATIONS
Remuneration for study services and expenses will be set forth in de tail in the Clinical Research 
Agreement. The Research Agreement will be signed by [CONTACT_079] [INVESTIGATOR_1238] a JJVC 
management representativ e prior to study initiation.
JJVC reserves the right to withhold remuneration fo r costs associated with protocol violations 
such as:
xContinuing an ineligible subject in the study. 
xScheduling a study visit outside the subjectâ€™s acceptable visit range. 
JJVC reserves the right to withhold final rem uneration until all study related activ ities have 
been completed, such as:
xQuery resolution. 
xCase Report Form signature. 
xCompletion of any follow-up action items. 
21. PUBLICATION
This is a multicenter study. The participating in stitution and Principal I nvestigations for this 
study agree that, should this study results be publ ished, the first publication of the results of 
this study shall be made in c onjunction with the presentation of  a joint, multicenter publication 
of the study results with the investigators and the institutions from all appropriate sites 
contributing data, analyses and comments. 
22. REFERENCES
1. ISO [ZIP_CODE]:2020: Clinical Investigati on of Medical Devices for Human 
Subjects â€” Good Clinical Pr actice. Available at 
https://www.iso.org/standard/[ZIP_CODE].html 
2. International Conference on Harmonization Good Clinical Practice E6 (ICH-GCP). Available at http://www.ich.org/produc ts/guidelines/efficacy /article/efficacy-
guidelines.html  3. Declaration of Helsinki - Ethical principles for Me dical Research Involving 
Human Subjects. Available at https:// www.wma.net/policies-post/wma-declaration-
of-helsinki-ethical-princ iples-for-medical-researc h-involving-human-subjects/ 
4. [LOCATION_002] (US) Code of Federa l Regulations (CFR). . Available at 
https://www.gpo.gov/fdsys/browse/collec tionCfr.action?collectionCode=CFR  
5. Wirth RJ, Edwards MC, Henderson M, Henderson T, Olivares G, Houts CR. Development of the Contact [CONTACT_169754]: CLUE Scales. Optom Vis Sci. 
2016;93(8):801-808. 
CR-6483, v 3.0  
Page 55 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
6.  SAS Institute Inc. 2016 SAS/STATÂ® 14.3 Userâ€™s Guide. Cary, NC: SAS 
Institute Inc.  
7. Health Information Portability and A ccountability Act (HIPAA). Available at 
https://www.hhs.gov/hipaa/for-professionals/privacy/index.html  8. Regulation (EU) 2017/745 of the European  Parliament and of  the Council of 5 
April 2017 on medical devices. Available at http://data.europa.eu/eli/reg/2017/745/2017-05-05 
CR-6483, v 3.0  
Page 56 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)
CR-6483, v 3.0  
Page 57 of 129JJVC CONFIDENTIAL
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 1
CR-6483, v 3.0  
Page 58 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 2
CR-6483, v 3.0  
Page 59 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 3
CR-6483, v 3.0  
Page 60 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 4
CR-6483, v 3.0  
Page 61 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 5
CR-6483, v 3.0 ) 
Page 62 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 6
CR-6483, v 3.0  
Page 63 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 7
CR-6483, v 3.0  
Page 64 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 8
CR-6483, v 3.0  
Page 65 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 9
CR-6483, v 3.0  
Page 66 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 10
CR-6483, v 3.0  
Page 67 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 11
CR-6483, v 3.0  
Page 68 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 12
CR-6483, v 3.0  
Page 69 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 13
CR-6483, v 3.0  
Page 70 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 14
CR-6483, v 3.0  
Page 71 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 15
CR-6483, v 3.0  
Page 72 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 16
CR-6483, v 3.0  
Page 73 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 17
CR-6483, v 3.0  
Page 74 of 129JJVC CONFIDENTIALClinical Study Protocol
35263(&,),&$7,2 )LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 18
CR-6483, v 3.0  
Page 75 of 129JJVC CONFIDENTIALClinical Study Protocol
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX B: PATIENT INSTRUCTION GUIDE   
The Patient Instruction Guide (PIG) will be provided separately. 
CR-6483, v 3.0  
Page 76 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)
DAILIES TOTAL 1
CR-6483, v 3.0  
Page 77 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 LENS FITTING CHARACTERISTICS
CR-6483, v 3.0  
Page 81 of 129JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 1of 5
CR-6483, v 3.0  
Page 82 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 2of 5
CR-6483, v 3.0  
Page 83 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 3of 5
CR-6483, v 3.0  
Page 84 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 4of 5
CR-6483, v 3.0  
Page 85 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 5of 5
CR-6483, v 3.0  
Page 86 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 SUBJECT REPORTED OCULAR SYMPTOMS/PROBLEMS
CR-6483, v 3.0  
Page 87 of 129JJVC CONFIDENTIAL
7LWOH6XEMHFW5HSRUWHG2FXODU6\PSWRP V3UREOHPV
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI



CR-6483, v 3.0  
Page 88 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
FRONT AND BACK SURFACE LENS DEPOSIT GRADING PROCEDURE  
CR-6483, v 3.0  
Page 89 of 129JJVC CONFIDENTIAL
Title:                        Front and Back Surface Lens Deposit Grading Procedure
Document Type:  
Document Number :  Revi sion Number:  4
Page 1of 4
CR-6483, v 3.0  
Page 90 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Title:                        Front and Back Surface Lens Deposit Grading Procedure
Document Type:  
Document Number :  Revi sion Number:  4
Page 2of 4
CR-6483, v 3.0  
Page 91 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Title:                        Front and Back Surface Lens Deposit Grading Procedure
Document Type:  
Document Number :  Revi sion Number:  4
Page 3of 4
CR-6483, v 3.0  
Page 92 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Title:                        Front and Back Surface Lens Deposit Grading Procedure
Document Type:  
Document Number :  Revi sion Number:  4
Page 4of 4
CR-6483, v 3.0  
Page 93 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 DETERMINATION OF DIST ANCE SPHEROCYLINDRICAL 
REFRACTIVE ERROR 
CR-6483, v 3.0  
Page 94 of 129JJVC CONFIDENTIAL
Title:                       Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number : Revi sion Number:  5
Page 1of5
CR-6483, v 3.0  
Page 95 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Title:                       Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number : Revi sion Number:  5
Page 2of5
CR-6483, v 3.0  
Page 96 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Title:                       Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number : Revi sion Number:  5
Page 3of5
CR-6483, v 3.0  
Page 97 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Title:                       Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number : Revi sion Number:  5
Page 4of5
CR-6483, v 3.0  
Page 98 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 BIOMICROSCOPY SCALE  
CR-6483, v 3.0  
Page 100 of 129JJVC CONFIDENTIAL
7LWOH  %LRPLFURVFRS\6FDOH
'RFXPHQW7\SH 
' R F X P H Q W  1 X P E H U    5 H Y L V L R Q  1 X P E H U      

CR-6483, v 3.0  
Page 101 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
7LWOH  %LRPLFURVFRS\6FDOH
'RFXPHQW7\SH 
' R F X P H Q W  1 X P E H U    5 H Y L V L R Q  1 X P E H U      

3DJHRI 

CR-6483, v 3.0  
Page 102 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
7LWOH  %LRPLFURVFRS\6FDOH
'RFXPHQW7\SH 
' R F X P H Q W  1 X P E H U    5 H Y L V L R Q  1 X P E H U      
3DJHRI 

CR-6483, v 3.0  
Page 103 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
7LWOH  %LRPLFURVFRS\6FDOH
'RFXPHQW7\SH 
' R F X P H Q W  1 X P E H U    5 H Y L V L R Q  1 X P E H U      

CR-6483, v 3.0  
Page 104 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
7LWOH  %LRPLFURVFRS\6FDOH
'RFXPHQW7\SH 
' R F X P H Q W  1 X P E H U    5 H Y L V L R Q  1 X P E H U      
3DJHRI 

CR-6483, v 3.0  
Page 105 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 DISTANCE AND NEAR SNELLEN VI SUAL ACUITY EVALUATION
CR-6483, v 3.0  
Page 106 of 129JJVC CONFIDENTIAL
7LWOH'LVWDQFHDQG1HDU6QHOOHQ9LVXD O$FXLW\(YDOXDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI
CR-6483, v 3.0  
Page 108 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
7LWOH'LVWDQFHDQG1HDU6QHOOHQ9LVXD O$FXLW\(YDOXDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI















CR-6483, v 3.0  
Page 109 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
7LWOH'LVWDQFHDQG1HDU6QHOOHQ9LVXD O$FXLW\(YDOXDWLRQ
'RFXPHQW7\SH 
'RFXPHQW1XPEHU  5HYLVLRQ1XPEHU
3DJHRI
























CR-6483, v 3.0  
Page 110 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
 PATIENT REPORTED OUTCOMES 
CR-6483, v 3.0  
Page 111 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
WHITE LIGHT LENS SURFACE WETTABILITY
CR-6483, v 3.0  
Page 113 of 129JJVC CONFIDENTIAL
Title: White Light Lens Surface Wettability
Document Type:
Document Number: Revision Number: 2
Page 1of 1
CR-6483, v 3.0  
Page 114 of 129JJVC CONFIDENTIALClinical Study Protocol 
[COMPANY_012] Vision Care, Inc.
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX E: IRIS COLOR SCALE
CR-6483, v 3.0  
Page 115 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX F: STARTING LENS POWER GUIDANCE
CR-6483, v 3.0  
Page 116 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
APPENDIX G: GUIDELINES FOR COVID-19 RISK MITIGATION
CR-6483, v 3.0  
Page 117 of 129JJVC CONFIDENTIAL
Clinical Study Protocol
[COMPANY_012] Vision Care, Inc.
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_19620]: CR-[ADDRESS_987005] lenses 
Version and Date: 3.[ADDRESS_987006] this study according to ISO [ZIP_CODE]:2020,
1GCP and ICH guidelines,2the 
Declaration of Helsinki,3[LOCATION_002] (US) Code of  Federal Regulations (CFR),4 and the 
pertinent individual country laws/regulations and to comply w ith its obligations, subject to 
ethical and safety considerations . The Principal Investigator [INVESTIGATOR_163064], including S ub-Investigators adhere to all ICH2regulations and GCP 
guidelines regarding clinical tria ls during and after study completion. 
I will assure that no deviation from or changes to the protocol will take place without prior 
agreement from the Sponsor and documented approval from the Institutional Review Board 
(IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants.
I am responsible for ensuring that all clinical site personnel including Sub-Investigators adhere 
to all ICH2regulations and GCP guidelines regarding clinical trials during and after study 
completion. All clinical site personnel involved in the conduct of this study have completed Human 
Subjects Protection Training.  I agree to ensure that all clinical site pe rsonnel involved in the conduct of this study are 
informed about their obligations in meeting the above commitments. I shall not disclose the information contained in this protocol or any results obtained from this 
study without written authorization. I have read the suggested guidance provided by [CONTACT_19610]-19 risk 
mitigation, (COVID-19 Work Instruction in the Appendix G of this protocol). I agree to 
conduct this study in compliance with local, state, governmental guida nce for COVID-19 risks.
Principal 
Investigator:
[INVESTIGATOR_722691] l Position (Printed)
Institution/Site:
Institution/Site Name
[CONTACT_16277]/Site Address
CR-6483, v 3.0  
Page 129 of 129JJVC CONFIDENTIAL